| Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults (NCT05281263) | Blue Lake Biotechnology Inc. | 2022-07-20 |
| MVA-BN-RSV Vaccine Trial (NCT05238025) | Bavarian Nordic | 2022-04-19 |
| A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy (NCT05229068) | GlaxoSmithKline | 2022-03-11 |
| Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults (NCT06033612) | Pfizer | 2021-11-12 |
| A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women. (NCT05045144) | GlaxoSmithKline | 2021-10-26 |
| Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial Virus (NCT05017519) | Mackay Memorial Hospital | 2021-10-01 |
| A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above (NCT05059301) | GlaxoSmithKline | 2021-10-01 |
| A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers (NCT04980391) | GlaxoSmithKline | 2021-08-03 |
| Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract (NCT04633187) | Enanta Pharmaceuticals, Inc | 2021-07-07 |
| Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects (NCT04914520) | Daiichi Sankyo Co., Ltd. | 2021-06-11 |
| Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above (NCT04886596) | GlaxoSmithKline | 2021-05-25 |
| Safety and Efficacy of BARS13 in the Elderly (NCT04681833) | Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. | 2021-05-24 |
| A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above (NCT04841577) | GlaxoSmithKline | 2021-04-27 |
| Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above (NCT04732871) | GlaxoSmithKline | 2021-02-15 |
| A Study of XW001 in Healthy Adult Subjects (NCT05642403) | Hangzhou Sciwind Biosciences Co., Ltd. | 2021-01-03 |
| Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study (NCT04657198) | GlaxoSmithKline | 2020-12-09 |
| A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers (NCT04605159) | GlaxoSmithKline | 2020-11-20 |
| Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults (NCT04785612) | Hvivo | 2020-11-10 |
| A Study of AK0529 in Chinese Infants Hospitalized With RSV (NCT04231968) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2020-09-22 |
| Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children (NCT04444284) | Meissa Vaccines, Inc. | 2020-06-09 |
| Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens (NCT04431050) | Imperial College London | 2020-02-21 |
| Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults (NCT04227210) | Meissa Vaccines, Inc. | 2020-01-14 |
| Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) (NCT04056611) | Janssen Sciences Ireland UC | 2019-12-26 |
| A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women (NCT04138056) | GlaxoSmithKline | 2019-11-05 |
| Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants (NCT04126213) | GlaxoSmithKline | 2019-11-05 |
| Predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in Infants (NCT04144816) | Hospices Civils de Lyon | 2019-10-01 |
| A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults (NCT04090658) | GlaxoSmithKline | 2019-09-25 |
| Pharmacokinetics and Safety of RV521 Formulations (NCT04065698) | Pfizer | 2019-08-13 |
| A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children (NCT03959488) | AstraZeneca | 2019-07-30 |
| A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infants and of RSV Surveillance (NCT03614676) | GlaxoSmithKline | 2019-05-30 |
| Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV (NCT03636906) | GlaxoSmithKline | 2019-04-08 |
| Anti-RSV Study in Chinese Patients (ASCENT) (NCT03699202) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2019-03-28 |
| A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults (NCT03814590) | GlaxoSmithKline | 2019-01-21 |
| Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection (NCT03656510) | Janssen Research & Development, LLC | 2018-11-29 |
| A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants (NCT03782662) | Pfizer | 2018-11-07 |
| Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients (NCT03715023) | Pulmocide Ltd | 2018-11-05 |
| A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women (NCT03674177) | GlaxoSmithKline | 2018-10-30 |
| A First in Human Study to Evaluate the Safety and Immune Response to a Vaccine for the Treatment of a Respiratory Virus, When Administered Into the Arm in Healthy Adult Participants (NCT04851977) | Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. | 2018-10-16 |
| Inpatient Challenge Study of rRSV A/Maryland/001/11, a Human Respiratory Syncytial Virus Challenge Strain, Administered to Healthy Adult Volunteers (NCT03624790) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-07-31 |
| A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus (NCT03379675) | Janssen Research & Development, LLC | 2018-02-06 |
| Music Therapy With Intubated and Sedated Pediatric Patients (NCT03629145) | Children's Healthcare of Atlanta | 2018-01-16 |
| A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection (NCT03332459) | Janssen Research & Development, LLC | 2018-01-05 |
| A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study (NCT03382431) | Pulmocide Ltd | 2017-11-14 |
| Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age (NCT03227029) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-09-22 |
| RESCEU: Defining the Burden of RSV Disease (NCT03698084) | University of Oxford | 2017-09-05 |
| RESCEU Study, Defining the Burden of Disease of RSV in Older Adults (NCT03621930) | UMC Utrecht | 2017-08-01 |
| RESCEU Study: Defining the Burden of Disease of Respiratory Syncytial Virus in Europe in Infants (NCT03627572) | UMC Utrecht | 2017-07-21 |
| A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection (NCT03258502) | Pfizer | 2017-07-19 |
| A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers (NCT03191383) | GlaxoSmithKline | 2017-07-11 |
| A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV (NCT03213405) | Pontificia Universidad Catolica de Chile | 2017-06-27 |
| Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age (NCT03102034) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-04-06 |
| RSV Antibiotic Drivers And Resource-use (NCT06977971) | Dr. Behcet Uz Children's Hospital | 2017-04-01 |
| A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants (NCT02927873) | GlaxoSmithKline | 2017-01-11 |
| A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. (NCT02878330) | MedImmune LLC | 2016-11-03 |
| Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age (NCT02890381) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-10-05 |
| Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age (NCT02948127) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-09-01 |
| RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults (NCT02873286) | Bavarian Nordic | 2016-09-01 |
| RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults. (NCT02864628) | Bavarian Nordic | 2016-09-01 |
| Specific Respiratory Infections as Triggers of Acute Medical Events (NCT02984280) | University College, London | 2016-09-01 |
| Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age (NCT02952339) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-08-01 |
| Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age (NCT02794870) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-07-15 |
| Viral Inhibition in Children for Treatment of RSV (NCT02654171) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2016-05-27 |
| Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women (NCT02753413) | GlaxoSmithKline | 2016-04-01 |
| A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus (NCT02673476) | Alios Biopharma Inc. | 2016-02-29 |
| A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection (NCT02593851) | Janssen Sciences Ireland UC | 2015-12-04 |
| A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization (NCT02624947) | Novavax | 2015-12-01 |
| Idylla IFV-RSV Panel Clinical Testing (NCT02786381) | Janssen Pharmaceutica N.V., Belgium | 2015-11-01 |
| Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children (NCT02601612) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-10-01 |
| A Study of AK0529 in Infants Hospitalized With RSV (NCT02460016) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2015-08-28 |
| Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants (NCT02325791) | Regeneron Pharmaceuticals | 2015-07-21 |
| Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection. (NCT02387606) | Janssen Sciences Ireland UC | 2015-05-07 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants (NCT02478333) | Janssen Pharmaceutical K.K. | 2015-05-01 |
| Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women (NCT02360475) | GlaxoSmithKline | 2015-03-20 |
| Safety, Tolerability and PK Study of AK0529 in Healthy Human (NCT02297594) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2014-10-01 |
| Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children (NCT02237209) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-09-01 |
| RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women. (NCT02247726) | Novavax | 2014-09-01 |
| Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children (NCT02040831) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-09-01 |
| A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176 (NCT02231671) | Alios Biopharma Inc. | 2014-08-31 |
| A Study of ALS-008176 in Infants Hospitalized With RSV (NCT02202356) | Alios Biopharma Inc. | 2014-07-23 |
| A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults (NCT02114268) | MedImmune LLC | 2014-04-01 |
| A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model (NCT02094365) | Alios Biopharma Inc. | 2014-03-01 |
| Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children (NCT01968083) | National Institute of Allergy and Infectious Diseases (NIAID) | 2013-10-03 |
| RSV F Dose-Ranging Study in Women (NCT01960686) | Novavax | 2013-10-01 |
| Infection With Respiratory Syncytial Virus in Infants (NCT04925310) | Hannover Medical School | 2013-10-01 |
| Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children (NCT01852266) | National Institute of Allergy and Infectious Diseases (NIAID) | 2013-10-01 |
| Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial) (NCT01915394) | Ankara University | 2013-09-01 |
| RSV Observational Study 2 (NCT01922648) | University of Oxford | 2013-06-01 |
| Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children (NCT01893554) | National Institute of Allergy and Infectious Diseases (NIAID) | 2013-06-01 |
| RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections. (NCT01805921) | ReiThera Srl | 2013-05-01 |
| Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV) (NCT01797419) | Gilead Sciences | 2013-05-01 |
| Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV) (NCT01756482) | Gilead Sciences | 2012-11-01 |
| Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age (NCT01754428) | Gilead Sciences | 2012-11-01 |
| Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge (NCT02755948) | Imperial College London | 2012-04-01 |
| Respiratory Syncytial Virus - RSV Protocol (NCT01502072) | M.D. Anderson Cancer Center | 2011-12-28 |
| A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers (NCT01355016) | MicroDose Therapeutx, Inc | 2011-09-01 |
| Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children (NCT01459198) | National Institute of Allergy and Infectious Diseases (NIAID) | 2011-08-01 |
| The Development of a Human Model of Respiratory Syncytial Virus Infection (NCT01349543) | Imperial College London | 2011-05-01 |
| Collection and Testing of Respiratory Samples (NCT01302418) | QIAGEN Gaithersburg, Inc | 2011-02-01 |
| Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine (NCT01290419) | Novavax | 2010-12-01 |
| RV568 - Viral Challenge With RSV (NCT01230645) | Respivert Ltd | 2010-10-01 |